

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 April 2025 (03.04.2025)



(10) International Publication Number
WO 2025/065045 A1

(51) International Patent Classification:

A61K 51/10 (2006.01) *A61P 35/00* (2006.01)
A61K 9/00 (2006.01) *C07K 16/40* (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/AU2023/050934

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

27 September 2023 (27.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant: **TELIX PHARMACEUTICALS (INNOVATIONS) PTY LTD** [AU/AU]; Level 4, 55 Flemington Road, North Melbourne, Victoria 3051 (AU).

(72) Inventors: **IVASHKEVICH, Alesia**; c/- Level 4, 55 Flemington Road, North Melbourne, Victoria 3051 (AU). **LE-TENDRE, Corinne**; c/- Level 4, 55 Flemington Road, North Melbourne, Victoria 3051 (AU). **GRIBBLE, Stuart Kent**; c/- Level 4, 55 Flemington Road, North Melbourne, Victoria 3051 (AU). **WHEATCROFT, Michael Paul**; c/- Level 4, 55 Flemington Road, North Melbourne, Victoria 3051 (AU).

(74) Agent: **FPA PATENT ATTORNEYS PTY LTD**; Level 19, South Tower, 80 Collins Street, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: NOVEL THERAPEUTIC TARGETS

(57) Abstract: The invention relates to proteins and compositions for the treatment of cancers that express carbonic anhydrase IX (CAIX), and methods of use thereof.

WO 2025/065045 A1